Side effects of Sputnik V, Oxford–AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran

[1]  E. El-Ghitany,et al.  COVID-19 vaccine acceptance rates and predictors among the Egyptian general population and Healthcare workers, the intersectionality of age and other factors , 2022, Scientific Reports.

[2]  Mitiku Desalegn,et al.  The prevalence of AstraZeneca COVID-19 vaccine side effects among Nigist Eleni Mohammed memorial comprehensive specialized hospital health workers. Cross sectional survey , 2022, PloS one.

[3]  A. Heidarzadeh,et al.  Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran , 2022, BMC Public Health.

[4]  Megha Jain,et al.  Acceptance and adverse effects following COVID-19 vaccination among the health care workers at a health care centre in the most backward district of India , 2022, Journal of family medicine and primary care.

[5]  K. Mathews,et al.  Identifying Strategies to Boost COVID-19 Vaccine Acceptance in the United States. , 2022, Rand health quarterly.

[6]  A. Tehrani-Banihashemi,et al.  Adverse effects following COVID-19 vaccination in Iran , 2022, BMC Infectious Diseases.

[7]  S. Omidvar,et al.  Acceptance of COVID-19 vaccine and determinant factors in the Iranian population: a web-based study , 2022, BMC Health Services Research.

[8]  H. Ansari,et al.  Adverse events following COVID-19 vaccination: A systematic review and meta-analysis , 2022, International Immunopharmacology.

[9]  J. Bawane,et al.  Cutaneous adverse effects of the available COVID‐19 vaccines in India: a questionnaire‐based study , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  Elliot Mbunge,et al.  Risk Factors for COVID-19 Infection Among Healthcare Workers. A First Report From a Living Systematic Review and meta-Analysis , 2022, Safety and Health at Work.

[11]  C. Locht,et al.  Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination , 2022, NPJ vaccines.

[12]  M. Taha,et al.  Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors , 2022, Vaccines.

[13]  Ashutosh Kumar Singh,et al.  Adverse events following immunization of COVID‐19 (Covaxin) vaccine at a tertiary care center of India , 2022, Journal of medical virology.

[14]  R. Caron,et al.  Challenges, Inquiry, and Recommendations: Effective COVID-19 Vaccine Management in the Face of Public Mistrust and Concern , 2022, Frontiers in Communication.

[15]  D. Nambiar,et al.  A rapid review of evidence on the determinants of and strategies for COVID-19 vaccine acceptance in low- and middle-income countries , 2021, Journal of global health.

[16]  R. Alizadeh-Navaei,et al.  Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran , 2021, Scientific Reports.

[17]  L. Moreno,et al.  Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain , 2021, Vaccines.

[18]  H. Zare,et al.  Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran , 2021, International Immunopharmacology.

[19]  D. F. Berhe,et al.  Adverse events of Oxford/AstraZeneca's COVID-19 vaccine among health care workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia , 2021, IJID Regions.

[20]  Ahmed N. Alghamdi,et al.  BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees , 2021, Frontiers in Medicine.

[21]  Mahmood Azimi,et al.  Adverse Effects of the COVID-19 Vaccine Reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan , 2021, Infection and drug resistance.

[22]  Isra Alghamdi,et al.  Adverse Events following AstraZeneca COVID-19 Vaccine in Saudi Arabia: A Cross-Sectional Study among Healthcare and Nonhealthcare Workers , 2021, Intervirology.

[23]  Tewodros Eshete,et al.  COVID-19 Vaccine: Side Effects After the First Dose of the Oxford AstraZeneca Vaccine Among Health Professionals in Low-Income Country: Ethiopia , 2021, Journal of multidisciplinary healthcare.

[24]  A. Joshi,et al.  Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review , 2021, Frontiers in Public Health.

[25]  Ziyang Feng,et al.  A comprehensive analysis of the efficacy and safety of COVID-19 vaccines , 2021, Molecular Therapy.

[26]  M. Mekhemar,et al.  Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers , 2021, Biology.

[27]  M. Merza,et al.  Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[28]  D. Gori,et al.  ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance , 2021, EClinicalMedicine.

[29]  N. Nath,et al.  Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study , 2021, Medical Journal Armed Forces India.

[30]  B. Saeed,et al.  Side effects and perceptions following Sinopharm COVID-19 vaccination , 2021, International Journal of Infectious Diseases.

[31]  N. Dar-Odeh,et al.  Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines , 2021, Vaccines.

[32]  B. Quiroga,et al.  COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects , 2021, Journal of Healthcare Quality Research.

[33]  David A. Drew,et al.  Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study , 2021, The Lancet Infectious Diseases.

[34]  C. Oh,et al.  Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System , 2021, Journal of Korean medical science.

[35]  Sameh Attia,et al.  Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic , 2021, Journal of clinical medicine.

[36]  L. Inbaraj,et al.  How safe is Covishield (ChAdOx1nCoV-19) Vaccine? Experience from a Tertiary Care Hospital in South India , 2021, medRxiv.

[37]  H. Elkout,et al.  Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database , 2021, medRxiv.

[38]  K. Ella,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial , 2021, The Lancet Infectious Diseases.

[39]  M. Sotir,et al.  First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[40]  V. Gushchin,et al.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.

[41]  K. Ella,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial , 2021, The Lancet Infectious Diseases.

[42]  G. Gabutti,et al.  Value of Immunizations during the COVID-19 Emergency , 2021, International journal of environmental research and public health.

[43]  J. Pell,et al.  Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants , 2020, Occupational and Environmental Medicine.

[44]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[45]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[46]  Wenling Wang,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.

[47]  Yuan Zhang,et al.  Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis , 2020, The Lancet.

[48]  A. Didierlaurent,et al.  The how’s and what’s of vaccine reactogenicity , 2019, npj Vaccines.

[49]  M. McHugh.  Interrater reliability: the kappa statistic , 2012, Biochemia medica.

[50]  Cheryl Tatano Beck,et al.  Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. , 2007, Research in nursing & health.

[51]  D. Stone,et al.  Design a questionnaire. , 1993, BMJ.

[52]  C. H. Lawshe.  A QUANTITATIVE APPROACH TO CONTENT VALIDITY , 1975 .

[53]  S. Figar,et al.  Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. , 2021, Medicina.

[54]  Witold Abramowicz,et al.  Challenges , 2007, Prehospital and Disaster Medicine.

[55]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.